EXEL · Exelixis, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-11-03 |
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
— Presentations to be webcast on www.exelixis.com — ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 3, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 3 rd Annual Healthcare |
| 2026-10-29 |
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million – – GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 – – Conference Call and Webcast Today at 5:00 PM ET – ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 29, 2026-- Exelixis, Inc. |
| 2026-10-15 |
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 15, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. |
| 2026-09-01 |
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 1, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21 st Annual Healthcare |
| 2026-08-31 |
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. ( Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. |
| 2026-08-05 |
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million - - GAAP Diluted EPS of $0.82, Non-GAAP Diluted EPS of $0.91 - - Conference Call and Webcast Today at 5:00 PM ET - ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 5, 2026-- Exelixis, Inc. |
| 2026-07-22 |
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. |
| 2026-06-22 |
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival ( OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 |
| 2026-05-30 |
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – ALAMEDA, Calif. --(BUSINESS WIRE)--May 30, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from a |
| 2026-05-27 |
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: |
| 2026-05-21 |
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif. --(BUSINESS WIRE)--May 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX ® (cabozantinib), and its |
| 2026-05-19 |
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – ALAMEDA, Calif. --(BUSINESS WIRE)--May 19, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a |
| 2026-05-07 |
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026: |
Past events
Source: https://ir.exelixis.com/